HeartWare International Reports Third Quarter Revenues of $7...(general and administrative expenses ...),Health

Date:11/4/2009

general and administrative expenses 3,149 3,181 11,721 7,993 Research and development expenses 3,646 5,478 9,994 14,801 ----- ----- ----- ------ Total operating expenses 6,795 8,659 21,715 22,794 Loss from operations (3,392) (8,571) (16,164) (22,706) Other income (expense): Foreign exchange gain (loss) 108 3,196 (260) 1,925 Interest expense (351) (2) (351) (17) Interest income 7 475 26 1,052 Change in fair value of derivative instrument (2,224) - (2,224) - Other, net (22) - (25) (92) --- -- --- --- Loss before income taxes (5,874) (4,902) (18,998) (19,838) Provision for income taxes - - - - -- -- -- -- Net loss $(5,874) $(4,902) $(18,998) $(19,838) ======= ======= ======== ======== Net loss per common share - basic and diluted $(0.60) $(0.57) $(2.07) $(2.61) ====== ====== ====== ====== Weighted average shares outstanding - basic and diluted 9,715,577 8,654,660 9,156,074 7,614,416 ========= ========= ========= =========

                        HEARTWARE INTERNATIONAL, INC.
                    CONDENSED CONSOLIDATED BALANCE SHEETS
                (in thousands except share and per share data)

                                            September 30, December 31,
                     
'/>"/>
SOURCE  HeartWare International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 
Related medicine technology :

1. Presentation of HeartWare Clinical Results
2. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
3. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
4. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
5. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
6. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
9. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
10. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
11. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference